Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

308 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of alteplase on survival after ischaemic stroke (IST-3): 3 year follow-up of a randomised, controlled, open-label trial.
Berge E, Cohen G, Roaldsen MB, Lundström E, Isaksson E, Rudberg AS, Slot KB, Forbes J, Smith J, Drever J, Wardlaw JM, Lindley RI, Sandercock PA, Whiteley WN; IST-3 Collaborative Group. Berge E, et al. Among authors: sandercock pa. Lancet Neurol. 2016 Sep;15(10):1028-34. doi: 10.1016/S1474-4422(16)30139-9. Epub 2016 Jul 20. Lancet Neurol. 2016. PMID: 27450474 Clinical Trial.
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
IST-3 collaborative group; Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A. IST-3 collaborative group, et al. Lancet. 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. Epub 2012 May 23. Lancet. 2012. PMID: 22632908 Free PMC article. Clinical Trial.
Third International Stroke Trial 3: an update.
Arauz A, Berge E, Sandercock P. Arauz A, et al. Curr Opin Neurol. 2014 Feb;27(1):8-12. doi: 10.1097/WCO.0000000000000045. Curr Opin Neurol. 2014. PMID: 24241447 Review.
Targeting recombinant tissue-type plasminogen activator in acute ischemic stroke based on risk of intracranial hemorrhage or poor functional outcome: an analysis of the third international stroke trial.
Whiteley WN, Thompson D, Murray G, Cohen G, Lindley RI, Wardlaw J, Sandercock P; IST-3 Collaborative Group. Whiteley WN, et al. Stroke. 2014 Apr;45(4):1000-6. doi: 10.1161/STROKEAHA.113.004362. Epub 2014 Mar 6. Stroke. 2014. PMID: 24603072 Free PMC article. Clinical Trial.
Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials.
Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg M, Lindley RI, Murray G, Olivot JM, Parsons M, Tilley B, Toni D, Toyoda K, Wahlgren N, Wardlaw J, Whiteley W, del Zoppo GJ, Baigent C, Sandercock P, Hacke W; Stroke Thrombolysis Trialists' Collaborative Group. Emberson J, et al. Lancet. 2014 Nov 29;384(9958):1929-35. doi: 10.1016/S0140-6736(14)60584-5. Epub 2014 Aug 5. Lancet. 2014. PMID: 25106063 Free PMC article. Review.
Alteplase for ischaemic stroke--responses.
Sandercock P, Lindley R, Wardlaw JM, Murray G, Whiteley W, Cohen G. Sandercock P, et al. Lancet. 2014 Aug 23;384(9944):660-1. doi: 10.1016/S0140-6736(14)61386-6. Lancet. 2014. PMID: 25152266 No abstract available.
308 results